Shingaki, Sumito
Koya, Junji
Yuasa, Mitsuhiro
Saito, Yuki http://orcid.org/0000-0003-2686-9604
Tabata, Mariko http://orcid.org/0000-0002-8013-7327
McClure, Marni B.
Ogawa, Seishi http://orcid.org/0000-0002-7778-5374
Katayama, Kotoe
Togashi, Yosuke
Imoto, Seiya
Kogure, Yasunori http://orcid.org/0000-0003-1158-5131
Kataoka, Keisuke
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (JP19K23979, JP21H05051, JP19K22573)
Foundation for Promotion of Cancer Research
Princess Takamatsu Cancer Research Fund
Japan Agency for Medical Research and Development (JP21ck0106542, JP19cm0106338)
National Cancer Center Research and Development Funds
Article History
Received: 19 July 2022
Revised: 8 November 2022
Accepted: 21 November 2022
First Online: 15 December 2022
Competing interests
: SO holds stock in Asahi Genomics, has patent applications for PD-L1 abnormalities as a predictive biomarker for immune checkpoint blockade therapy, and has received research funding from Dainippon-Sumitomo Pharmaceutical and Cordia Therapeutics. K Kataoka holds stock in Asahi Genomics, has patent applications for PD-L1 abnormalities as a predictive biomarker for immune checkpoint blockade therapy, and has received research funding from Otsuka Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Chordia Therapeutics, and Bristol-Myers Squibb. The other authors declare no competing financial interests.